Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
35 EUR | +1.16% |
|
-4.89% | -30.00% |
06-20 | SARTORIUS VORZUEGE : UBS remains Neutral | ZD |
06-20 | Sartorius stabilizes after previous day's price slide | DP |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 61.96 and 42.74 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.00% | 15.09B | - | ||
-53.99% | 2.27B | C+ | ||
+17.78% | 1.86B | - | ||
-14.23% | 1.43B | - | ||
+21.99% | 1.25B | B+ | ||
-25.52% | 857M | - | ||
+2.14% | 792M | - | ||
-37.13% | 718M | - | C- | |
+23.11% | 595M | C+ | ||
-29.71% | 589M | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- SRT4 Stock
- Ratings Sartorius AG